Autism

Bionano Announces OGM Roadshow, TOUR, which Provides Education on the Company’s Workflow and Helps Build a Community of Users

SAN DIEGO, July 31, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the successful launch of its…

1 year ago

Center for Autism & Related Disorders, LLC. – CARD® Receives Court Approval of Sale to Pantogran LLC, Proud Moments ABA, and New Story

Pantogran, LLC, led by Founder Dr. Doreen Granpeesheh, to Acquire 112 CARD Centers and All CARD Intellectual Property Proud Moments ABA…

1 year ago

Bionano to Present at the Canaccord Genuity 43rd Annual Growth Conference

SAN DIEGO, July 27, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that Erik Holmlin, Ph.D., Bionano’s president…

1 year ago

PaxMedica Announces Positive Top Line Results from the PAX-101 (intravenous suramin) Phase 3 African Sleeping Sickness Study, PAX-HAT-301

The study’s primary endpoint was reached and demonstrated statistically significant and clinically meaningful resultsThese results pave the way for filing…

1 year ago

First of its kind study into digital self-management support for autistic adults reveals significant improvements in anxiety levels and quality of life

Clinical study by Cornwall NHS Trust and University of Plymouth finds anxiety, self-injurious behaviour, memory, and orientation problems are reduced…

1 year ago

PaxMedica Grants Exclusive Pharmacy Distribution Rights for PAX-101 to Vox Nova, LLC

·   Agreement for PAX-101 (suramin IV) Distribution in the U.S. for up to 7 years ·   VoxNova will be responsible…

1 year ago

Bionano Announces the Stratys™ System for OGM and VIA™ Software for Hematologic Malignancies

The Stratys™ instrument for optical genome mapping (OGM) will enable a four-fold increase in raw data generation rate compared to…

1 year ago

PaxMedica Comments on Common Stock Volatility

Engages ShareIntel to Track Market Activity TARRYTOWN, NY, June 22, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- PaxMedica, Inc. (Nasdaq:…

1 year ago

SciSparc Announces IRB Approval to Conduct its Phase IIb Trial in Tourette Syndrome

Company reaches another clinical trial milestone for treatment of Tourette’s with its novel SCI-110 therapy in the United States TEL…

1 year ago

PaxMedica CEO Interviewed by The BRAIN Foundation

Webcast Link Available at PaxMedica.com TARRYTOWN, NY, June 20, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – PaxMedica, Inc. (Nasdaq: PXMD),…

1 year ago